<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881659</url>
  </required_header>
  <id_info>
    <org_study_id>IEC 12-27</org_study_id>
    <nct_id>NCT01881659</nct_id>
  </id_info>
  <brief_title>Cervical Cancer Screening With Human Papillomavirus Testing</brief_title>
  <acronym>ESTAMPA</acronym>
  <official_title>Multicentric Study of Cervical Cancer Screening and Triage With Human Papillomavirus (HPV) Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Agency for Research on Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Agency for Research on Cancer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HPV testing for primary cervical cancer screening of women over 30 years of age is likely to
      become the standard of care in the near future in many areas of the world. Its high
      sensitivity can significantly improve the effectiveness of screening programs and its
      prolonged negative predictive value can allow extension of screening intervals. However, a
      single HPV test has low positive predictive value and can lead to unnecessary workup and
      over-treatment and generate unnecessary distress. This multi-centric study will screen 50,000
      women with HPV testing and compare several triage approaches that can follow HPV testing in
      order to make an HPV-based screening programme efficient, affordable and sustainable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in several Latin American countries. Currently, the study has
      started in one site in Colombia and soon another site in Mexico will start. In each
      participating center, women aged 30-64 years who are attending clinics for cervical screening
      will be invited to participate in the study. Women who agree to participate and sign the
      corresponding Institutional Review Board (IRB) approved consent forms will undergo a pelvic
      examination, and cervical cells for primary screening and triage will be collected.
      Recruitment specimens will be used for primary screening with an established HPV DNA test
      (Food and Drug Administration FDA approved). All women who are HPV-positive by the
      recruitment test will be referred for a standardized colposcopy examination for diagnosis. At
      the colposcopy visit, but before colposcopy is performed, a risk factor interview will be
      administered and participants will undergo visual inspection of the cervix with acetic acid
      (VIA) and collection of additional cervical cells and a blood specimen. The results of VIA
      will not be disclosed to the colposcopist. During colposcopy, the colposcopists will obtain
      (2-4) biopsies from any abnormally-appearing areas to ascertain neoplastic outcomes (CIN3+)
      and to direct treatment as required. All women who attend colposcopy will have a second round
      of HPV testing approximately 18 months after recruitment and those who are HPV-positive will
      be referred to colposcopy for final diagnosis. Data management and study supervision will be
      the responsibility of the International Agency for Research on Cancer (IARC) and the local
      Principal Investigators, most of whom are experienced HPV researchers.

      The combined number of histologically-confirmed diagnoses of CIN3+, including CIN2 lesions
      positive for p16, (estimated n=500) will be the outcome of primary interest for evaluation of
      the performance of the various triage modalities. Our initial analyses will focus on
      comparisons of triage strategies that employ a single method: VIA, conventional/liquid-based
      cytology, HPV DNA genotyping, HPV RNA detection, detection of E6 proteins of high risk HPV
      types, or markers of HPV-induced cell-cycle alterations (e.g., p16, ki67, etc). To the extent
      possible, molecular testing for HPV triage will be carried out on the recruitment specimens
      to simulate a 'reflex testing' approach wherein screening and triage are done on the same
      specimen without additional visits. Subsequent analyses will consider various alternative
      strategies that employ more than one triage methodology; e.g., HPV DNA genotyping followed by
      cytology. The effectiveness and costs of each alternative strategy will be assessed under
      various scenarios of feasibility, cost, and effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with histologically confirmed cervical intraepithelial neoplasia grade 3 or cancer (CIN3+), including CIN2 positive for p16, on reviewed histology</measure>
    <time_frame>Detected after initial HPV screening or at second screening round 18 months since entry</time_frame>
    <description>There will be two HPV screening rounds. Women who test negative for HPV at initial screening will finish their participation. HPV positive women will be: 1) referred to colposcopy, 2) invited for a second HPV screening round if not yet treated, and 3) referred to final colposcopy if HPV positive at second screening. Clinical management will be based on local histology.
Histology specimens will be externally reviewed by one highly experience international pathologist. If the local and external results are the same, this will become the final histology. If there is disagreement, the specimen will be sent to a third pathologist (be blinded to previous readings). The final diagnosis will then be that agreed by two pathologists (local and either external or both external). Remaining discrepancies will be solved by adjudication at a multi-headed microscope. Worst histology on review will be used to define outcome measures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with histologically confirmed CIN2, CIN3 or cancer (CIN2+) on reviewed histology</measure>
    <time_frame>Detected after initial HPV screening or at second screening round 18 months since entry</time_frame>
    <description>There will be two HPV screening rounds. Women who test negative for HPV at initial screening will finish their participation. HPV positive women will be: 1) referred to colposcopy, 2) invited for a second HPV screening round if not yet treated, and 3) referred to final colposcopy if HPV positive at second screening. Clinical management will be based on local histology.
Histology specimens will be externally reviewed by one highly experience international pathologist. If the local and external results are the same, this will become the final histology. If there is disagreement, the specimen will be sent to a third pathologist (be blinded to previous readings). The final diagnosis will then be that agreed by two pathologists (local and either external or both external). Remaining discrepancies will be solved by adjudication at a multi-headed microscope. Worst histology on review will be used to define outcome measures.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50000</enrollment>
  <condition>CIN3</condition>
  <condition>CIN2</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Women attending cervical screening</arm_group_label>
    <description>Women aged 30-64 years who signed informed consent and comply with inclusion and exclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HPV screening</intervention_name>
    <description>Women who signed informed consent will be screened with HPV testing.</description>
    <arm_group_label>Women attending cervical screening</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Three cervical samples will be collected at entry (one dry and two liquid-based). Sample
      retaining or discharge will depend on HPV test (done in first liquid sample) results. If HPV
      positive (and 2% of HPV negatives): 1) the dry sample will be used for the E6 protein strip
      test, 2) the first liquid sample remains will be used for liquid-based cytology and the
      p16/ki67 test and, 3) 10 aliquots from the second liquid sample will be stored. If HPV
      negative: 1) the dry sample will be stored for the E6 strip test until the end of the study.
      Testing will be done based on evidence towards usefulness in primary screening, 2) two
      aliquots from the first liquid sample will be stored and, 3) the second liquid sample will be
      discharged. At initial colposcopy, a cervical sample (6 aliquots) and a 10mL blood sample
      (serum, plasma and buffy-coat) will be collected and stored. All stored samples will be used
      for testing of triage techniques, either currently available or develop in the near future.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This is a multicentric study to be carried out in countries across the Latin American
        region. At each site, a census of all women 28-64 years of age residents of the selected
        area will be done previously to the start of the study. All women will then be invited
        using different approaches to the local health centers where screening is to happen.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 30-64 years

          -  Mentally competent to be able to understand the consent form

          -  Able to communicate with study staff

          -  Physically able to have a pelvic exam

        Exclusion Criteria:

          -  Reporting no previous sexual activity

          -  History of cervical cancer

          -  Previous treatment for cervical pre-cancer in the last six months

          -  Hysterectomy

          -  Plans to move out of the study area in the next 12 months

          -  Screened for cervical cancer in the last 12 months (depending on local regulations)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rolando Herrero, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Agency for Research on Cancer (IARC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rolando Herrero, MD, PhD</last_name>
    <phone>+33472738683</phone>
    <email>herreror@iarc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maribel Almonte, PhD</last_name>
    <phone>+33472738492</phone>
    <email>almontem@iarc.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopsital de Clinicas</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvio Tatti, MD</last_name>
      <phone>00541141944409</phone>
      <email>siltatti@fibertel.com.ar</email>
    </contact>
    <contact_backup>
      <last_name>Laura Fleider, MD</last_name>
      <email>laurafleider@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Silvio Tatti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Fleider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucia Cardinal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insituto Malbran - Hospital Posadas</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra Picconi, PhD</last_name>
      <phone>00541148319421</phone>
      <email>mapicconi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Mural, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad San Francisco Xavier de Chuquisaca</name>
      <address>
        <city>Sucre</city>
        <country>Bolivia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carolina Teran, PhD</last_name>
      <email>carolina.teran@gmx.net</email>
    </contact>
    <investigator>
      <last_name>Carolina Teran, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ministerio de Salud</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorena Baez, MD</last_name>
      <phone>0056225740473</phone>
      <phone_ext>240473</phone_ext>
      <email>lorena.baez@minsal.cl</email>
    </contact>
    <investigator>
      <last_name>Lorena Baez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carla Molina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute of Colombia</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Wiesner, MD</last_name>
      <phone>+5713341111</phone>
      <phone_ext>4001</phone_ext>
      <email>cwiesner@cancer.gov.co</email>
    </contact>
    <contact_backup>
      <last_name>Yuly Salgado, BSc</last_name>
      <phone>00573144252404</phone>
      <email>milesal495@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carolina Wiesner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuly Salgado, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Martinez, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauricio Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcela Cellis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad de Antioquia</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria I Sanchez, PhD</last_name>
      <phone>+5742196062</phone>
      <email>sanchezg@une.net.co</email>
    </contact>
    <investigator>
      <last_name>Gloria I Sanchez, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Social Security Institute of Costa Rica</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis B Saenz, MD</last_name>
      <phone>+50622223353</phone>
      <email>lbsaenz@ccss.sa.cr</email>
    </contact>
    <contact_backup>
      <last_name>Alejandro Calderon, MD</last_name>
      <phone>+50622223353</phone>
      <email>ajcalder@ccss.sa.cr</email>
    </contact_backup>
    <investigator>
      <last_name>Luis B Saenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Calderon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad Nacional Autonoma de Honduras</name>
      <address>
        <city>Tegucigalpa</city>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annabelle Ferrera, PhD</last_name>
      <phone>+50499902713</phone>
      <email>bozaferrera@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yessy Cabrera, MSc</last_name>
      <email>yessycabrera21@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Annabelle Ferrera, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yessy Cabrera, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Odessa Henriquez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacqueline Figueroa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jafet Ortiz, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Salud Publica de Mexico</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelio Cruz, MD, PhD</last_name>
      <phone>+527773293020</phone>
      <phone_ext>3108</phone_ext>
      <email>acruz@insp.mx</email>
    </contact>
    <investigator>
      <last_name>Aurelio Cruz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Lazcano Ponce, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asuncion</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Kasamatsu, MD</last_name>
      <phone>+59521446459</phone>
      <email>ekasabalbo@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Laura Mendoza, PhD</last_name>
      <phone>+595971274244</phone>
      <email>lauramendozatorres@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Elena Kasamatsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Mendoza, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Isabel Rodriguez, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Soilan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Malvina Paez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laboratorio Central de Salud Publica</name>
      <address>
        <city>Asuncion</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Villagra, PhD</last_name>
      <phone>00595982744675</phone>
      <email>vevillagra@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Nelly Maldonado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Villagra, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Liz Bobadilla, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liga Nacional de Lucha contra el Cancer</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gino Venegas, MD</last_name>
      <phone>0051998254182</phone>
      <email>ginovenegas@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yenny Bellido</last_name>
      <phone>0051947452286</phone>
      <email>investigacion@ligacancer.org.pe</email>
    </contact_backup>
    <investigator>
      <last_name>Javier Arias Stella, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria de la Luz Miraval, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gino Venegas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yenny Bellido, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorge Ferrandiz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Romero, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comision Honoraria de Lucha contra el Cancer</name>
      <address>
        <city>Montevideo</city>
        <zip>11200</zip>
        <country>Uruguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Rodriguez, MD</last_name>
      <phone>+59824020807</phone>
      <email>rodriguezg@urucan.org.uy</email>
    </contact>
    <contact_backup>
      <last_name>Dolores Larrosa</last_name>
      <phone>+59824020807</phone>
      <email>doloreslarrosa@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guillermo Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Beracochea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalia Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bolivia</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Honduras</country>
    <country>Mexico</country>
    <country>Paraguay</country>
    <country>Peru</country>
    <country>Uruguay</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2013</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>cancer prevention</keyword>
  <keyword>cervical screening</keyword>
  <keyword>HPV testing</keyword>
  <keyword>triage techniques</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

